Download presentation
Presentation is loading. Please wait.
Published byLanny Yulia Budiaman Modified over 5 years ago
1
Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma
Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD Journal of Thoracic Oncology Volume 13, Issue 8, Pages e150-e152 (August 2018) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Mutation ensemble for response to PD-1 inhibition in thymic carcinoma. (A) TMB by targeted sequencing of 206 genes is highly correlated with TMB by WES in thymic epithelial tumors in TCGA database. TMB by targeted sequencing showed higher correlation with TMB by WES in thymic carcinoma. (B) TMB in thymic carcinoma (n = 35) does not predict response to anti–PD-1 treatment. (C) cyclin dependent kinase inhibitor 1B (CDKN1B), CYLD lysine 63 deubiquitinase (CYLD), and SET domain containing 2 (SETD2) mutations were associated with objective response to pembrolizumab, but BAP1, GTF2I, IGF2R, and TP53 were associated with poor response. Mutational status of seven genes was mutually exclusive. CR, complete response; PD progressive disease; PD-1, programmed cell death 1; PR partial response; SD stable disease; TC, thymic carcinoma; TCGA, The Cancer Genome Atlas; TMB, tumor mutation burden; TET, thymic epithelial tumor; WES whole exome sequencing. Journal of Thoracic Oncology , e150-e152DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.